Evidence map›Paper›PMID 42876859›Full record

ArticleFrontiers in immunology2026

IL-23 and monocyte interactions redirect human Th17.1 cells to an IL-17A

Bennie van Heeswijk, Wida Razawy, Nadine Davelaar, Anne-Marie M C Mus, Patrick S Asmawidjaja, Pieter J M Leenen, Erik Lubberts

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bennie van HeeswijkDepartment of Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Wida RazawyDepartment of Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Nadine DavelaarDepartment of Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Anne-Marie M C MusDepartment of Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Patrick S AsmawidjajaDepartment of Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Pieter J M LeenenDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Erik LubbertsDepartment of Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: IL-23-targeted therapies have demonstrated clinical efficacy in psoriatic arthritis (PsA), primarily through the reduction of IL-17A-driven inflammation. Consequently, most studies have focused on classical, high IL-17A-producing, CCR6 Methods: Peripheral blood mononuclear cells (PBMCs) from treatment-naive patients with early PsA were stimulated in the presence of IL-23 or anti-IL-23 antibody before quantifying IL-17A and IFN-γ secretion. Additionally, human memory CCR6 Results: As expected, IL-23 stimulation induced IL-17A in PsA PBMCs, whereas IL-23 inhibition reduced IL-17A secretion but did not affect IFN-γ. In healthy donor PBMCs, ex vivo IL-23R expression was restricted to memory CCR6 Conclusion: IL-23 exerts distinct effects on Th17.1 compared to Th17 cells. We show a role for IL-23 in IFN-γ upregulation in Th17.1 cells, which is reversed in the presence of monocytes. In co-culture with monocytes, Th17.1 cells progress to a pathogenic IL-17A

Indexed as

Arthritis, PsoriaticCell CommunicationInterferon-gammaInterleukin-17Interleukin-23MonocytesTh17 CellsCells, CulturedHumansImmunologic MemoryIL17A protein, humanInterferon-gammaInterleukin-17Interleukin-23CCR6IFN-γIL-17AIL-23monocyteplasticitypsoriatic arthritisTh17.1

Identifiers

PMID42876859
PMCPMC13661559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.